Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update
TORONTO and CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended December 31, 2022 (the company’s fiscal Q3 2023) and provide additional business updates to shareholders and other stakeholders. All dollar amounts in this press release are in US dollars unless specified otherwise.
Related news for (MEDXF)
- Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
- Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
- Medexus Announces New License Deal for Topical Terbinafine
- Medexus Announces US$58.5 million in New Credit Facilities
- Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022